XML 29 R22.htm IDEA: XBRL DOCUMENT v3.24.3
Redeemable Noncontrolling Interest (Tables)
 9 Months Ended
Sep. 30, 2024
Noncontrolling Interest [Abstract]  
Summary of company and transfers to noncontrolling interest The following is a summary of net income attributable to the Company and transfers to noncontrolling interest (in thousands):

 

 

For the Three Months Ended September 30,

 

 

For the Nine Months Ended September 30,

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Net loss available to Class A ordinary shareholders

$

(17,910

)

 

$

(10,984

)

 

$

(39,908

)

 

$

(29,767

)

(Increase)/Decrease in ProKidney Corp. accumulated deficit for impact of
   subsidiary equity-based compensation

 

851

 

 

 

2,629

 

 

 

3,865

 

 

 

7,848

 

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for exchange
   of Common Units in ProKidney LP for Class A ordinary shares

 

(454

)

 

 

(64

)

 

 

(15,356

)

 

 

(64

)

(Increase)/Decrease in ProKidney Corp. additional paid-in capital for vesting of
   Restricted Common Units in ProKidney LP

 

766

 

 

 

21

 

 

 

14,839

 

 

 

(4,457

)

Change from net loss available to Class A ordinary shareholders and change
   in ownership interest in ProKidney LP

$

(16,747

)

 

$

(8,398

)

 

$

(36,560

)

 

$

(26,440

)